By Dr Deepu
Bloomberg News (9/20, Bennett) reported that Roche Holding AG announced that Esbriet (pirfenidone)” reduces the risk of death by 38 percent after two years of treatment for patients with idiopathic pulmonary fibrosis,” according to clinical data to be presented at a medical conference in Amsterdam.
No comments:
Post a Comment
Please leave your comments